Date | Price Target | Rating | Analyst |
---|---|---|---|
1/14/2022 | $25.00 | Buy | HC Wainwright & Co. |
12/23/2021 | $25.00 | Overweight | Cantor Fitzgerald |
11/1/2021 | $24.00 | Outperform | SVB Leerink |
9/13/2021 | $30.00 | Buy | Laidlaw |
8/25/2021 | $26.00 | Buy | B. Riley Securities |
8/13/2021 | $33.00 → $30.00 | Buy | Chardan Capital |
SC TO-I/A - Vincerx Pharma, Inc. (0001796129) (Subject)
SC TO-I/A - Vincerx Pharma, Inc. (0001796129) (Subject)
8-K - Vincerx Pharma, Inc. (0001796129) (Filer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
Gainers Vaxart (NASDAQ:VXRT) shares increased by 146.7% to $1.85 during Thursday's after-market session. The market value of their outstanding shares is at $327.1 million. Venus Concept (NASDAQ:VERO) stock rose 10.32% to $0.95. The company's market cap stands at $6.0 million. Vincerx Pharma (NASDAQ:VINC) stock moved upwards by 5.99% to $0.73. The market value of their outstanding shares is at $21.5 million. Kintara Therapeutics (NASDAQ:KTRA) shares rose 5.82% to $0.2. The company's market cap stands at $10.9 million. Beyond Air (NASDAQ:XAIR) shares moved upwards by 5.64% to $1.31. The company's market cap stands at $60.1 million. Soligenix (NASDAQ:SNGX) stock rose 5.42% to $4.38. The m
Vincerx Pharma (NASDAQ:VINC) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.29) by 100 percent. This is a 14.71 percent increase over losses of $(0.68) per share from the same period last year.
SC 13G - Vincerx Pharma, Inc. (0001796129) (Subject)
SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)
SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)
Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMDC) VIP236, with data expected at the end of Q3 2024 Expected cash runway through 2024 PALO ALTO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the second quarter of 2024 and provided an overview of its clinical programs and anticipated milestones. "During the second quarter, our team focused on execution and the c
Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC) The National Institutes of Health (NIH) and Vincerx announced positive results from enitociclib Phase 1 combination study, reporting a fourth partial response (PR) in a patient with peripheral T-cell lymphoma (PTCL) Vincerx reported the first PR in a patient with transformed follicular lymphoma (tFL) in its Phase 1 dose-escalation study of enitociclib as a monotherapy Recent financing provides expected cash runway through 2024 PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- V
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC) today announced the pricing of an underwritten public offering of (i) 6,000,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 6,000,000 shares of common stock, and (ii) to certain investors, pre-funded warrants to purchase up to an aggregate of 16,000,000 shares of common stock and accompanying common stock warrants to purchase up to an aggregate of 16,000,000 shares of common stock. Each share of common stock and accompanying common stock warrant are being sold together at a combined public offering price of $0.75, and each pre-funded warrant and accompa
HC Wainwright & Co. initiated coverage of Vincerx Pharma with a rating of Buy and set a new price target of $25.00
Cantor Fitzgerald initiated coverage of Vincerx Pharma with a rating of Overweight and set a new price target of $25.00
SVB Leerink initiated coverage of Vincerx Pharma with a rating of Outperform and set a new price target of $24.00